Research Tracker›Biomarker Atlas›Long COVID›C-Reactive Protein (CRP)

C-Reactive Protein (CRP) in Long COVID

C-Reactive Protein (CRP), also described as Acute phase protein, is a inflammatory marker reported as elevated in Long COVID (PASC, Post-Acute Sequelae of COVID-19) when patients are compared with healthy controls, recovered individuals without persistent symptoms. The cited literature links this alteration to general inflammation marker. This entry summarises Lai et al. 2023. Group-level associations like this do not translate into an individual diagnostic cut-off.

↑ ElevatedInflammatoryLOINC 1988-5

Summary

Direction in Long COVID↑ Elevated — higher than in the comparison group
CategoryInflammatory
Also described asAcute phase protein
Compared againstHC, R (healthy controls, recovered individuals without persistent symptoms)
Associated symptomsGeneral inflammation marker
Test typeBlood test (serum / plasma / whole blood)
LOINC code1988-5
SourceLai et al. 2023 — doi:10.3389/fmed.2023.1085988
Condition atlasLong COVID Biomarker Atlas

Other conditions where CRP is reported

See the cross-condition hub: CRP across conditions.

Trials, interventions and tests

In clinical-trial registrations this marker maps to the outcome term C-Reactive Protein (21 registered trials use a matching outcome measure).

Clinical trials using C-Reactive Protein (CRP) as an outcome

13 more trials reference this marker.

Interventions studied alongside this marker

Hypothesis-generating links from trial outcome usage and literature co-occurrence. Not treatment recommendations.

Commercial test availability

C-Reactive Protein (CRP) — commercial laboratory test.

Links are for reference only; availability, specimen requirements and coverage vary by location.

Related Inflammatory markers in Long COVID

Full list: Long COVID Biomarker Atlas.

Frequently asked questions

Is C-Reactive Protein (CRP) high or low in Long COVID?

Elevated. Studies summarised in the OSMF atlas report higher C-Reactive Protein (CRP) in Long COVID than in healthy controls, recovered individuals without persistent symptoms. Source: Lai et al. 2023.

What symptoms is C-Reactive Protein (CRP) associated with in Long COVID?

The cited literature associates this marker with General inflammation marker. These are population-level associations and do not mean the marker causes the symptoms.

Which test measures C-Reactive Protein (CRP)?

It is measured as a blood test (serum / plasma / whole blood). The standard laboratory code is LOINC 1988-5. Commercial laboratories such as Quest Diagnostics, LabCorp, Ulta Lab Tests list an orderable assay.

Is one abnormal C-Reactive Protein (CRP) result diagnostic of Long COVID?

No. No single biomarker is diagnostic of Long COVID. C-Reactive Protein (CRP) findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Is C-Reactive Protein (CRP) specific to Long COVID?

No. The same marker is also reported in Atrial Fibrillation, COPD, Gulf War Illness, Inflammatory Bowel Disease (Crohn's/UC), Low Back Pain, Lyme Disease, ME/CFS, Major Depressive Disorder, Osteoarthritis, Rheumatoid Arthritis in this atlas, so it reflects shared biology (for example inflammation or vascular stress) rather than a condition-specific signature.

Cite this page

Open Source Medicine Foundation. (2026). C-Reactive Protein (CRP) in Long COVID: direction, evidence and what it means. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/long-covid/c-reactive-protein-crp.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-06-29 · Page generated from long-covid.json · Browse: Long COVID atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.